治疗诊断学市场报告：趋势、预测和竞争分析（至 2030 年）

治疗诊断学和预测

全球治疗诊断学市场的未来充满希望，肿瘤学和非肿瘤学市场充满机会。到 2030 年，全球治疗诊断学市场预计将达到 55 亿美元，2024 年至 2030 年复合年增长率为 17.3%。该市场的主要驱动力是癌症盛行率的增加、临床试验数量的增加以及对精准医疗的认识和采用的不断提高。

• 在放射性同位素类别中，Lucintel 预计，由于镏-177 产品的可用性和采用率不断增加，镏-177 在预测期内将出现最高增长。
• 从应用来看，肿瘤学仍然是一个很大的领域。
• 按地区划分，预计北美在整个预测期内仍将是最大的地区。这是由于高效成像技术的日益采用，以及该地区对精准医疗的日益关注。

治疗诊断学市场的策略性成长机会

治疗诊断学市场在多种应用中提供了各种策略成长机会。透过利用这些机会，我们可以扩大治疗诊断学治疗的领域并提高其影响。

• 肿瘤学应用：扩大治疗诊断学在肿瘤学中的应用，特别是难以治疗的癌症，可以解决未满足的医疗需求，并透过强化和高效的治疗来推动市场成长。
• 心臟病学：循环系统领域治疗诊断学解决方案（例如心肌灌注造影）的发展开拓了新的市场领域，并增强了心血管疾病的诊断和治疗。
• 神经病学：在神经病学中，治疗诊断学具有巨大的发展潜力，它可以提供准确的诊断和治疗，特别是在神经退化性疾病的影像和治疗方面。
• 感染疾病：将治疗诊断学扩展到结核病和病毒感染疾病等感染疾病，可以支持癌症的早期发现并促进癌症的早期治疗，从而开闢了传统肿瘤学之外的一系列应用领域。
• 农村医疗保健服务：使用行动装置和远端医疗将治疗诊断学产品引入农村和服务不足的地区可以减少医疗保健差距，同时扩大市场范围。

总之，这些趋势预示着策略性成长前景，将推动各个医学专业（尤其是放射学）的创新。透过满足多样化的医疗需求，市场可以实现永续成长，并对全球健康产生更大的影响。

治疗诊断学市场的驱动因素与挑战

各种技术、经济和监管因素正在影响治疗诊断学市场。了解这些市场驱动因素和挑战对于成功驾驭市场并实现永续成长至关重要。

推动治疗诊断学市场的因素是：

1.技术进步：治疗诊断学製造技术、诊断影像方法、标靶治疗等方面的创新正在提高其有效性并推动市场扩张。

2.癌症发生率上升：全球癌症患者数量的增加推动了对治疗诊断学等标靶治疗方法的需求，扩大了该领域使用的放射性同位素的市场。

3. 政府支持：政府透过监管激励和融资加大对核子医学和精准肿瘤学发展的支持，支持放射性同位素产业的成长。

4. 医疗保健全球化：全球医疗合作正在扩大治疗诊断学治疗的可近性，特别是在开发中国家。

5. 患者对个人化医疗的需求：患者对个人化、微创治疗的需求不断增加，推动了治疗诊断学的采用，放射治疗学提供了量身定制的治疗方案。

治疗诊断学市场面临的挑战是：

1. 生产成本高：生产放射性同位素和开发放射肿瘤药物的高成本限制了可负担性和可近性，对市场成长带来了挑战。

2.核准障碍：对放射性材料的审批和安全处理的严格监管要求可能会延迟新治疗方法的推出。

3. 供应链挑战：半衰期短和生产设施有限可能导致供不应求和无法获得治疗方法。

总之，儘管面临高製造成本和监管障碍等挑战，但治疗诊断学市场仍受到技术进步和个人化医疗需求不断增长的推动。应对这些因素对于市场相关人员实现持续成长并为患者提供创新治疗至关重要。

目录

第一章执行摘要

第二章全球治疗诊断学市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 市场趋势及预测分析（2018-2030）

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球治疗诊断学市场趋势（2018-2023）与预测（2024-2030）
• 全球治疗诊断学市场：依放射性同位素分类
  • 碘131
  • 碘123
  • 镓68
  • 镏177
  • 18F配备Y-90
  • 其他的
• 全球治疗诊断学市场：按方法
  • 标靶治疗
  • 针对性诊断
• 全球治疗诊断学市场：依应用分类
  • 瘤
  • 除肿瘤外

第四章 各地区市场趋势及预测分析（2018-2030）

• 全球治疗诊断学市场：按地区
• 北美治疗诊断学市场
• 欧洲治疗诊断学市场
• 亚太地区放射治疗诊断学市场
• 其他地区治疗诊断学市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球治疗诊断学市场成长机会：按放射性同位素
  • 全球治疗诊断学市场成长机会：依方法
  • 全球治疗诊断学市场成长机会：依应用分类
  • 全球治疗诊断学市场成长机会：按地区
• 全球治疗诊断学市场的新兴趋势
• 战略分析
  • 新产品开发
  • 扩大全球治疗诊断学市场的产能
  • 全球治疗诊断学市场的企业合併
  • 认证和许可

第七章主要企业简介

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

Radiotheranostic Trends and Forecast

The future of the global radiotheranostic market looks promising with opportunities in the oncology and non-oncology markets. The global radiotheranostic market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 17.3% from 2024 to 2030. The major drivers for this market are the increasing prevalence of cancer, the rising number of clinical trials, and the growing awareness and adoption of precision medicines.

• Lucintel forecasts that, within the radioisotope category, lutetium-177 is expected to witness the highest growth over the forecast period due to the increasing availability and adoption of lu-177 products.
• Within the application category, oncology will remain the larger segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the increasing adoption of efficient imaging technologies along with a growing inclination towards precision medicine in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radiotheranostic Market

Emerging trends in the radiotheranostics market are reshaping its future applications and dynamics:

• Precision Oncology: One of these trends is precision oncology, which uses radiotheranostics to target cancerous cells specifically, thus sparing healthy tissues from harm. It has become a cornerstone in modern cancer therapy, as it leads to better patient outcomes with fewer side effects.
• Globalization of Radioisotope Supply: This globalization ensures that the supply chains of radioisotopes are broader, leading to the availability of radiotheranostics therapies from any part of the world. Such efforts help mitigate potential shortages through the diversification of sources, ensuring consistent access to treatments globally.
• Integration with Digital Health: The introduction of AI and telemedicine among digital health technologies into radiotheranostics allows for better diagnosis and treatment planning. These innovations facilitate real-time monitoring and more accurate dosimetry, resulting in improved therapeutic outcomes.
• Expansion Beyond Oncology: The use of radiotheranostics has extended beyond oncology into cardiology, neurology, and infectious diseases. This creates new opportunities and expands the reach of these interventions.
• Patient-Centric Care Models: We are seeing the introduction of patient-centered care models based on personalized treatment plans and a multispecialty approach in the radiotheranostics field. These models are raising patient satisfaction levels and improving adherence to therapeutic protocols, which in turn enhances therapeutic outcomes.

In conclusion, these trends are revolutionizing radiotheranostics and making it a cornerstone of personalized medicine, gradually penetrating diverse fields of medicine.

Recent Developments in the Radiotheranostic Market

The radiotheranostics market is rapidly evolving, with several key developments shaping its growth and impact. These advancements have increased the effectiveness of treatment and expanded access to radiotheranostics therapies.

• Novel Radiation Theragnostic Agents: The development of new radiation theragnostic agents, specifically for prostate and neuroendocrine tumors, has resulted in more precise treatment and better outcomes for patients.
• Advanced Manufacturing Techniques: Advanced radioisotope production techniques have increased the availability of critical isotopes, such as Lutetium-177 and Gallium-68, which are used for cancer diagnosis, reducing costs and widening access to these therapies.
• Regulatory Approvals: Simplified regulatory proceedings in key markets have facilitated faster approval of radiotherapeutics, enabling swift access to novel treatments for patients.
• Strategic Collaborations: Strategic alliances between pharmaceutical companies, research institutions, and healthcare service providers aim to foster innovation while enhancing the development and delivery of radioactive therapeutics.
• Global Market Expansion: Growing investment in nuclear medicine infrastructure globally, coupled with the adoption of therapies in emerging markets, has necessitated global growth in radiotheranostics.

In conclusion, these key developments are strongly impacting the radiotheranostics market by fueling innovation, increasing access, and improving patient outcomes. As the market continues to grow, these changes will be instrumental in shaping its future.

Strategic Growth Opportunities for Radiotheranostic Market

A variety of strategic growth opportunities exist within multiple applications across the radiotheranostics market. Tapping into these opportunities can expand the sector and increase the influence of radiotheranostics therapies.

• Oncology Applications: Expanding radiotherapeutic applications for oncology, especially for hard-to-treat cancers, can address unmet medical needs and stimulate market growth through focused and efficient treatment.
• Cardiology: The development of radiotheranostics solutions in cardiology, such as for myocardial perfusion imaging, will open up new market areas and enhance the diagnosis and treatment of cardiovascular conditions.
• Neurology: In neurology, there is great potential for the growth of radiotheranostics, particularly with respect to imaging and treating neurodegenerative diseases, providing both accurate diagnostics and therapy.
• Infectious Diseases: Expanding radiotheranostics into infectious diseases, such as tuberculosis and viral infections, will assist in early detection and promote early cancer treatment, widening the scope beyond traditional oncology applications.
• Rural Healthcare Access: The use of mobile units or telemedicine to bring radiotheranostics into rural and underserved areas would reduce healthcare disparities while expanding the market reach.

In conclusion, these trends present strategic growth prospects that are driving innovation within various medical specialties, particularly radiography. By addressing diverse healthcare needs, the market can achieve sustainable growth and have a broader impact on global health.

Radiotheranostic Market Driver and Challenges

Various technological, economic, and regulatory factors affect the radiotheranostics market. Understanding these drivers and challenges is essential for navigating the market successfully and achieving sustainable growth.

The factors responsible for driving the radiotheranostic market include:

1. Technological Advancements: Innovations in radiation therapeutics production techniques, imaging methods, and targeted therapies have enhanced their effectiveness, stimulating market expansion.

2. Rising Cancer Incidence: The global increase in cancer cases demands more target-oriented therapies like radiotherapy, resulting in larger markets for radioisotopes used in this area.

3. Government Support: Increasing government assistance for the promotion of nuclear medicine and precision oncology through regulatory incentives and financing is boosting the growth of the radiotheranostics industry.

4. Globalization of Healthcare: Global healthcare collaborations have opened up access to radiotheranostics therapies, especially in developing nations.

5. Patient Demand for Personalized Medicine: Growing patient demand for personalized, minimally invasive treatments is driving the adoption of radiotheranostics, which offer tailored therapeutic options.

Challenges in the radiotheranostic market include:

1. Expensive Production Costs: The high cost of producing radioisotopes and developing radiotheranostics agents can limit affordability and access, posing a challenge to market growth.

2. Obstacles in Approvals: Stringent regulatory requirements for approval and the safe handling of radioactive materials can delay the introduction of new therapies.

3. Supply Chain Challenges: These include short half-life periods and limited production facilities, creating the potential for shortages and leading to treatment unavailability.

In conclusion, the radiotheranostics market is driven by technological advancements and the rising demand for personalized medicine, while facing challenges such as high production costs and regulatory hurdles. Successfully navigating these factors is essential for market players to achieve sustainable growth and deliver innovative treatments to patients.

List of Radiotheranostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiotheranostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiotheranostic companies profiled in this report include-

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

Radiotheranostic by Segment

The study includes a forecast for the global radiotheranostic by radioisotope, approach, application, and region.

Radiotheranostic Market by Radioisotope [Analysis by Value from 2018 to 2030]:

• Iodine-131
• Iodine-123
• Gallium-68
• Lutetium-177
• 18F With Y-90
• Others

Radiotheranostic Market by Approach [Analysis by Value from 2018 to 2030]:

• Targeted Therapeutic
• Targeted Diagnostic

Radiotheranostic Market by Application [Analysis by Value from 2018 to 2030]:

• Oncology
• Non-Oncology

Radiotheranostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiotheranostic Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major radiotheranostics producers in key regions: the USA, China, India, Japan, and Germany:

• United States: The FDA has approved several radiotheranostics therapies for prostate cancer and neuroendocrine tumors, among others. This has been made possible by increasing funding in research and academic-industry partnerships that foster the development of next-generation radiotheranostics.
• China: China's investment in its nuclear medicine infrastructure includes the domestic production of radioisotopes. Recently, the country has established centers for radiotheranostics therapies through collaborations with global firms, meeting the rising demand for precise oncology care delivery.
• Germany: Institutions like the Deutsches Krebsforschungszentrum (German Cancer Research Center) have taken leadership roles in conducting clinical trials for new agents used in radiotheranostics. The country is also improving its regulatory framework to expedite patient access to modern treatments.
• India: Government-driven initiatives aimed at enhancing nuclear medicine capabilities are positioning India as a key player in the growing radiotheranostics domain. Recent developments include affordable radiotheranostics solutions and collaborations with overseas partners to boost technical know-how.
• Japan: Japan has seen progress in radioisotope production and distribution, among other developments, all aimed at integrating radiotheranostics into personalized medicine. Government support for research and the development of novel radiotheranostics agents is driving market growth, particularly in oncology.

Features of the Global Radiotheranostic Market

Market Size Estimates: Radiotheranostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiotheranostic market size by radioisotope, approach, application, and region in terms of value ($B).

Regional Analysis: Radiotheranostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotope, approaches, applications, and regions for the radiotheranostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiotheranostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiotheranostic market by radioisotope (iodine-131, iodine-123, gallium-68, lutetium-177, 18F with Y-90, and others), approach (targeted therapeutic and targeted diagnostic), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiotheranostic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radiotheranostic Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radiotheranostic Market by Radioisotope
  • 3.3.1: Iodine-131
  • 3.3.2: Iodine-123
  • 3.3.3: Gallium-68
  • 3.3.4: Lutetium-177
  • 3.3.5: 18F with Y-90
  • 3.3.6: Others
• 3.4: Global Radiotheranostic Market by Approach
  • 3.4.1: Targeted Therapeutic
  • 3.4.2: Targeted Diagnostic
• 3.5: Global Radiotheranostic Market by Application
  • 3.5.1: Oncology
  • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radiotheranostic Market by Region
• 4.2: North American Radiotheranostic Market
  • 4.2.1: North American Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.2.2: North American Market by Application: Oncology and Non-oncology
• 4.3: European Radiotheranostic Market
  • 4.3.1: European Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.3.2: European Market by Application: Oncology and Non-oncology
• 4.4: APAC Radiotheranostic Market
  • 4.4.1: APAC Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.4.2: APAC Market by Application: Oncology and Non-oncology
• 4.5: ROW Radiotheranostic Market
  • 4.5.1: ROW Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.5.2: ROW Market by Application: Oncology and Non-oncology

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiotheranostic Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Radiotheranostic Market by Approach
  • 6.1.3: Growth Opportunities for the Global Radiotheranostic Market by Application
  • 6.1.4: Growth Opportunities for the Global Radiotheranostic Market by Region
• 6.2: Emerging Trends in the Global Radiotheranostic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiotheranostic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiotheranostic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Bayer
• 7.3: Progenics Pharmaceuticals
• 7.4: Telix Pharmaceuticals Limited
• 7.5: ITM Radiopharma
• 7.6: Life Molecular Imaging
• 7.7: RadioMedix